The largest database of trusted experimental protocols

23 protocols using olaparib azd2281

1

Cisplatin, Olaparib, and MK-2206 Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cisplatin was obtained from Calbiochem/EMD Millipore (Billerica, MA, USA). Olaparib (AZD-2281), a selective PARP1/PARP2 inhibitor, and MK-2206, a selective inhibitor of AKT1/AKT2/AKT3, were obtained from Selleck Chemicals (Houston, TX, USA).
+ Open protocol
+ Expand
2

Synthesis and Characterization of Olaparib-BODIPY Conjugates

Check if the same lab product or an alternative is used in the 5 most similar protocols
Unless otherwise noted, all reagents were purchased from Sigma-Aldrich (St. Louis, MO) and used without further purification. BODIPY FL and BODIPY 650/665 succinimidyl ester were purchased from Invitrogen (Carlsbad, CA). Olaparib (AZD2281) was purchased from Selleck Chemicals (Houston, TX). 4-[[4-Fluoro-3-(piperazine-1-carbonyl)phenyl]methyl]-2H-phthalazin-1-one and olaparib-BODIPY FL were synthesized as described elsewhere (40 –42 (link)). HPLC-ESI-MS analyses and HPLC purifications were performed on a Waters (Milford, MA) LC-MS system. For LC-ESI-MS analyses, a Waters XTerra® C18 5 μm column was used. For preparative runs, an Atlantis® Prep T3 OBDTM 5 μM column was used. High-resolution ESI mass spectra were obtained on a Bruker Daltonics APEXIV 4.7 Tesla Fourier Transform mass spectrometer (FT-ICR-MS) in the Department of Chemistry Instrumentation Facility at the Massachusetts Institute of Technology. Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Varian AS-400 (400 MHz) spectrometer. Chemical shifts for protons are reported in parts per million (ppm) and are referenced against the dimethylsulfoxide lock signal (1H, 2.50 ppm). Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, m = multiplet), coupling constants (Hz) and integration.
+ Open protocol
+ Expand
3

Lung Cancer Cell Lines and PARP Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
H23 and H522 lung adenocarcinoma cells, as well as SK-MES-1 squamous lung cancer cells were obtained from ATCC (Manassas, VA, USA). They were grown in RPMI 1640 supplemented with glutamine and 10% fetal bovine serum at 37°C in a humidified atmosphere consisting of 5% CO2 and 95% air. Cell lines were validated by STR profiling at the MD Anderson Cancer Center core facilities and routinely tested for mycoplasma. The PARP inhibitors olaparib (AZD2281) and talazoparib (BMN673) were purchased from Selleckchem (Houston, TX, USA). BMN673 and AZD2281 were dissolved in dimethyl sulfoxide (DMSO) and kept as 10 mmol/L stock solutions in small aliquots at −20°C. The following primary antibodies were used: phosphorylated RAD17 (p-RAD17), p-CHK2, cleaved caspase-3 (Cell Signaling Technology, Danvers, MA, USA), RAD51, γH2AX antibody (Millipore), and p-RPA32 (Bethyl Laboratories, Montgomery, TX, USA). The transfection reagent Lipofectamine 3000 was purchased from Life Technologies (Carlsbad, CA, USA).
+ Open protocol
+ Expand
4

Olaparib and Veliparib Storage Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Olaparib/AZD2281 (Selleckchem, S1060) and veliparib/ABT-888 (Enzo Life Sciences, ALX-270-444-M001) were stored at −80° C in single use aliquots.
+ Open protocol
+ Expand
5

Synchronized DNA damage induction

Check if the same lab product or an alternative is used in the 5 most similar protocols
MCF7 and HeLa cells were grown in DMEM supplemented with 10% FBS. 4-OHT (Sigma, St Louis, MO) was added to a final concentration of 1 μM. Shield-1 (Cheminpharma, New Haven, CT) was added to a final concentration of 1 μM for 3 h to stabilize the ddI-PpoI fusion protein. ON-TARGETplus SMARTpool siRNA towards Brca1, NBS1, Rap80, ATM (Dharmacon, Boulder, CO) or ON-TARGETplus Non-targeting siRNA (Dharmacon, Boulder, CO) was transfected into cells using Dharmafect-1 transfection reagent (Dharmacon, Boulder, CO) according to manufacturer's protocols to a final concentration of 100 nM. Olaparib (AZD2281) (Selleckchem, Houston, TX) and CP466722 (22 (link)) were added to the tissue culture medium at a final concentration of 5 μM 1 h prior to I-PpoI induction and remained in the medium for the duration of the experiment.
+ Open protocol
+ Expand
6

Measuring SW480 Cell Proliferation

Check if the same lab product or an alternative is used in the 5 most similar protocols
SW480 cell proliferation was measured using the Cell Counting Kit-8 (CCK-8) cell proliferation kit (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. Cells were seeded in 96-well plates at 1 × 103 cells/well with 100 μL complete medium and cultured at 37°C, and then 10 μL CCK-8 solution was added to each well after 24, 72, and 96 hours. Plates were incubated at 37°C for 2 hours, and then the absorbance at 450 nm was measured with a microplate reader (Bio-Rad, La Jolla, CA, USA). The PARP1 inhibitor olaparib (AZD2281) was obtained from Selleckchem (Houston, TX, USA). All experiments were performed in triplicate, and three independent repeat experiments were performed.
+ Open protocol
+ Expand
7

Breast Cancer Cell Line Cultures and Treatments

Check if the same lab product or an alternative is used in the 5 most similar protocols
ER+ MCF7 (originally obtained from the Barbara A. Karmanos Cancer Institute, Detroit, MI, USA), MCF7(2) (a MCF7 derivative cell line that shows increased sensitivity to estrogen; [18 (link)] and TNBC cell lines, MDA-MB-231 and MDA-MB-468 (originally obtained from American Type Culture Collection, Manassas, VA, USA), were provided by the Tissue Culture Shared Resources at Georgetown University Medical Center. ER+ breast cancer cells line, MDA-MB-175, was purchased from American Type Culture Collection (ATCC; Manassas, VA, USA). All cell lines were grown in IMEM (Life Technologies, Grand Island, NY, USA; A10489-01) media supplemented with 5% fetal bovine serum. BOLD-100 (formerly IT-139, NKP1339 and KP1339) was provided by Intezyne Biosciences, Inc. (Tampa, FL, USA). For in vitro assays, dimethyl sulfoxide (DMSO) was used at the diluent and negative control (0.2%). Olaparib (AZD-2281) was purchased from Selleck (Houston, TX, USA). All cells were authenticated by DNA fingerprinting and tested regularly for Mycoplasma infection. All other chemicals were purchased from Sigma-Aldrich.
+ Open protocol
+ Expand
8

Comprehensive Drug Compound Library

Check if the same lab product or an alternative is used in the 5 most similar protocols
Buparlisib (BKM120, #S2247), olaparib (AZD2281, #S1060), doxorubicin (Adriamycin, #S1208), NU7026 (#S2893), KU-60019 (#S1570), imatinib (STI571, #S1026) were from Selleck Chemicals. Rapamycin (sirolimus, #GC15031) was from GlpBio Technology. 6-hydroxy-DL-dopa (#H2380), ATR inhibitor IV (#504972), 5-(1,3-diaryl-1H-pyrazol-4-yl)hydantoin (DPH) (#SML0202) and tetracycline hydrochloride (#T3383) were from Millipore Sigma.
+ Open protocol
+ Expand
9

Colony Formation Assay after IR and PARPi

Check if the same lab product or an alternative is used in the 5 most similar protocols
For the colony formation assay following IR, iMEFs were plated in 60mm dishes, irradiated after 24 hr with the indicated doses and incubated at 37°C in the presence of 5% CO2. After 14 days, colonies were fixed with 15% acetic acid: methanol (v/v) for 5 min and stained with 0.5% Crystal Violet (Sigma-Aldrich) for 30 min for colony visualization. For the colony formation assay in the presence of PARPi (Olaparib/AZD2281, Selleckchem), 0.1, 1, and 5 μM PARPi was added 24 after seeding and cells allowed to grow for 14 days before fixation, with fresh media and PARPi replenished on day 7.
+ Open protocol
+ Expand
10

Breast Cancer Cell Lines and PARP Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
We studied 14 human breast cancer cell lines: 3 BRCA1 mutant lines with BRCA1 allelic loss (HCC-1947, MDA-MB-436, and SUM-149PT), 1 BRCA2 mutant line with BRCA2 allelic loss (HCC-1428), 9 BRCA wild-type lines with BRCA1 allelic loss (MCF-7, ZR75, MDA-MB-361, BT-474, SKBR3, MDA-MB-231, BT-549, MDA-MB-468 and BT-20), and 1 BRCA wild-type line without BRCA1 allelic loss (T47D). T47D, MCF-7, ZR75, MDA-MB-361, BT-474, SKBR3, MDA-MB-231, BT-549, MDA-MB-468, and BT-20 cells were cultured at 37°C in DMEM supplemented with 10% FBS in a humid incubator with 5% CO2. SUM-149PT cells were cultured in Ham’s F-12 supplemented with 5% FBS, insulin, and hydrocortisone. The PARP inhibitors veliparib (ABT-888), olaparib (AZD2281), and iniparib (BSI-201) were purchased from Selleck Chemicals (Houston TX, USA).
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!